You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Danoprevir/r

Showing 1 - 25 of 2,777
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Hepatitis C Trial (Danoprevir, Ritonavir, peginterferon alfa-2a)

Completed
Has Results
  • Chronic Hepatitis C
  • (no location specified)
Feb 28, 2021

Chronic Hepatitis C Trial (Ravidasvir, Danoprevir, Ritonavir)

Completed
Has Results
  • Chronic Hepatitis C
  • (no location specified)
Oct 20, 2020

HCV Trial in Beijing (Ravidasvir, Danoprevir, Ritonavir)

Completed
  • HCV
  • Beijing, Beijing, China
    Peking University People's hospital
Jul 25, 2020

Healthy Trial (Ravidasvir, Danoprevir, Ritonavir)

Completed
  • Healthy
  • (no location specified)
Jun 27, 2018

Chronic Hepatitis C Trial (Danoprevir, Ritonavir, peginterferon alfa-2a)

Completed
Has Results
  • Chronic Hepatitis C
  • (no location specified)
Jun 27, 2018

Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

Recruiting
  • Acute Myeloid Leukemia
  • CLL1 and CD38 dual-target CAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023

DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Apr 10, 2023

PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,

Not yet recruiting
  • PD-1 Refractory Advanced Melanoma
  • Responder-Derived Fecal microbiota transplantation (R-FMT
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 1, 2023

AML, MDS Trial in Tianjin (XZB-0004)

Not yet recruiting
  • AML
  • MDS
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 13, 2023

Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Relapsed/Refractory Large B-cell Lymphoma
  • (no location specified)
Oct 6, 2023

Radiotherapy, Breast Cancer, Relaxation Trial in Munich (Respiratory training and relaxation techniques under adjuvant radiation

Recruiting
  • Radiotherapy
  • +3 more
  • Respiratory training and relaxation techniques under adjuvant radiation therapy in DIBH in breast cancer
  • Munich, Germany
    Department of Radiation Oncology, Technical University of Munich
Aug 1, 2023

Lymphoma Trial in Beijing, Shanghai City, Seoul (Obinutuzumab, Glofitamab, Rituximab)

Recruiting
  • Lymphoma
  • Beijing, China
  • +2 more
Oct 12, 2023

Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas Trial (KT-253)

Not yet recruiting
  • Myeloid Malignancies
  • +3 more
  • (no location specified)
Mar 22, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +9 more
  • Adelaide, Australia
  • +12 more
Jan 6, 2023

Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

Not yet recruiting
  • Marginal Zone Lymphoma
  • Mosunetuzumab + Lenalidomide
  • +3 more
  • (no location specified)
Aug 16, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Nociception Coma Scale-Revised With Personalized Stimulus

Recruiting
  • Disorder of Consciousness
  • Nociception Coma Scale-Revised
  • Rome, Italy
    Rita Formisano
Aug 24, 2023

Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma Trial in Worldwide (AZD4573)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Relapsed/Refractory Classical Hodgkins Lymphoma
  • Duarte, California
  • +33 more
Jan 5, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 23, 2023

Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

Completed
Has Results
  • Non-Hodgkin's Lymphoma, Relapsed
  • +8 more
  • PBCAR20A
  • +2 more
  • Duarte, California
  • +4 more
Jan 4, 2023

Relmacabtagene Autoleucel in Patients With LBCL

Recruiting
  • Large B-cell Lymphoma
  • Relmacabtagene Autoleucel
  • Shanghai, Shanghai, China
    Ruijin Hospital Affiliated to Shanghai Jiao Tong University Scho
Nov 15, 2023

Follicular Lymphoma (FL) Trial (biological, drug, other)

Not yet recruiting
  • Follicular Lymphoma (FL)
  • Tisagenlecleucel
  • +4 more
  • (no location specified)
May 24, 2023

B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))

Active, not recruiting
  • B-Cell Lymphoma
  • Non-Hodgkin Lymphoma
  • Birmingham, Alabama
  • +23 more
Dec 2, 2022

Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent Trial in Italy (R-DHAP, Pola-R-DHAP)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma Refractory
  • Diffuse Large B-cell Lymphoma Recurrent
  • Alessandria, Italy
  • +39 more
Jul 28, 2023

B-cell Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin)

Recruiting
  • B-cell Non-Hodgkin Lymphoma
  • Mosunetuzumab (IV)
  • +4 more
  • Birmingham, Alabama
  • +28 more
Jan 6, 2023